ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Approves olaparib for gBRCAm Metastatic Pancreatic Adenocarcinoma americanpharmaceuticalreview
January 03, 2020The U.S. Food and Drug Administration (FDA) has approved olaparib (LYNPARZA?, AstraZeneca Pharmaceuticals) for the maintenance treatment of adult patients with deleterious or ... -
Pfizer’s Talzenna cleared for breast cancer
pharmatimes
October 19, 2018US regulators have approved Pfizer’s PARP inhibitor Talzenna to treat patients with breast cancer carrying a certain mutation, identified by a companion diagnostic developed by Myriad.
Pharma Sources Insight January 2025
